This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Frost & Sullivan Applauds Galena Biopharma For Its Breakthrough Breast Cancer Vaccine, NeuVax™

MOUNTAIN VIEW, Calif., March 12, 2013 /PRNewswire/ -- Based on its recent analysis of the breast cancer vaccines market, Frost & Sullivan recognizes Galena Biopharma, Inc. (NASDAQ: GALE) with the 2013 Global Frost & Sullivan Award for New Product Innovation. The company's revolutionary product, NeuVax™, has the potential to address a huge unmet medical need for a breast cancer vaccine and provide significant cost-savings to both patients and governments.

NeuVax (nelipepimut-S or E75), a nonapeptide, derived from the human epidermal growth factor receptor 2 (HER2) oncogene, is co-administered with the immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) in an intradermal injection. It is the first breast cancer vaccine to reach Phase III clinical trials and could very well emerge as an off-the-shelf cancer immunotherapy treatment to prevent recurrence.

In Phase II studies, NeuVax was shown to prevent or delay breast cancer recurrence in women with early-stage, high-risk (node positive), HER2 low-to-intermediate (immunohistochemical (IHC) 1+/2+ or fluorescent in situ hybridization (FISH) <2.2) disease. NeuVax immunotherapy uses the patient's own immune system to target tumor cells in a highly-specific, less toxic and more-convenient way than conventional cancer therapies.

"Based on Phase II results, the U.S. Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment for a Phase III study, for which patient enrollment has already begun," said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "This 700-patient study has a primary endpoint of disease-free survival (DFS) after 139 events or three years—the timeframe within which the disease is likely to relapse in approximately 25 percent of patients."

Multiple clinical trials have proven that NeuVax is safe and effective in stimulating cytotoxic (CD8+) T-cells in a highly specific manner to target HER2 expressing cells. After establishing statistical significance in the prevention of recurrence of breast cancer in 24-month and 36-month periods, the 60-month Phase 1/2 trial demonstrated a 5.6 percent recurrence rate, compared to a 25.9 percent recurrence rate in the control arm.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.37 +48.78 0.29%
S&P 500 1,980.11 +1.20 0.06%
NASDAQ 4,457.0950 +12.1860 0.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs